Ropivacaine

Ropivacain is a potent sodium channel blocker. Ropivacain blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese[1][2]. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane[3]. Ropivacaine is used for the research of neuropathic pain management[1].

Product Specifications

CAS Number

[84057-95-4]

UNSPSC

12352005

Hazard Statement

H302

Target

Potassium Channel; Sodium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Cardiovascular Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/ropivacaine.html

Purity

99.98

Solubility

DMSO : 12.5 mg/mL (ultrasonic)

Smiles

O=C([C@H]1N(CCC)CCCC1)NC2=C(C)C=CC=C2C

Molecular Formula

C17H26N2O

Molecular Weight

274.40

Precautions

H302

References & Citations

[1]Li TF, et al. Epidural sustained release ropivacaine prolongs anti-allodynia and anti-hyperalgesia in developing and established neuropathic pain. PLoS One. 2015 Jan 24;10 (1) :e0117321.|[2]Milan Patel, et al. Ropivacaine Inhibits Pressure-Induced Lung Endothelial Hyperpermeability in Models of Acute Hypertension. Life Sci. 2019 Apr 1;222:22-28.|[3]Dene Simpson, et al. Ropivacaine: a review of its use in regional anaesthesia and acute pain management. Drugs. 2005;65 (18) :2675-717.|[4]Hye Won Shin, et al. The inhibitory effects of bupivacaine, levobupivacaine, and ropivacaine on K2P (two-pore domain potassium) channel TREK-1. J Anesth

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Citation 01

In Vitro Cell Dev Biol Anim. 2024 Oct;60 (9) :1109-1120.|Int J Neuropsychopharmacol. 2025 Oct 1;28 (10) :pyaf066.|J Toxicol Sci. 2023;48 (3) :139-148.|BMC Pregnancy Childbirth. 2025 Jun 2;25 (1) :646.|Eur Spine J. 2022 Nov;31 (11) :2960-2971.|J Exp Clin Cancer Res. 2024 Mar 25;43 (1) :90.|Stem Cell Res Ther. 2021 Feb 4;12 (1) :107.